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Plain English Summary
Patients usually understand their disease and lifestyle needs better than many medical professionals. They also have
important ideas about what research would be most beneficial to their lives, especially on how to manage
symptoms in a way that improves daily quality of life. In the UK, the National Institute for Health Research has
recognised the value of patient insight, and now requires researchers with public funding to involve patients and
the public throughout the research process. There are many opportunities for involvement, but these generally
focus on improving study design to ensure the trial is acceptable to participants. Some programmes work towards
setting research priorities as important to patients, public members, and medical experts, but due to the complexity
and cost involved in running clinical trials, the majority of research originates with the pharmaceutical industry or
academic institutions. There is a clear mismatch between research ideas that patients prioritise (quality of life), and
those actually investigated (drug development).
The Patient Led Research Hub (PLRH) is a new initiative hosted by the Cambridge Clinical Trials Unit. The PLRH
supports research ideas as proposed by patient organisations, providing resources and expertise in research design
and delivery. The PLRH aims to co-produce any technically feasible project, regardless of disease or symptom focus.
The proposing patient group maintains ownership of the project with an active role in study management. This
method of research has proven to produce credible research studies that are of direct relevance to patients.
Abstract
Patient and Public Involvement has become an indispensable and expected component of healthcare research in
the United Kingdom, largely driven by the National Institute of Health Research and other research funders.
Opportunities for patients to become involved in research abound, and many organisations now have dedicated
‘public involvement’ teams. However, its value is often questioned amidst criticism of tokenism and the recognition
that a mismatch persists between patient priorities and funded research. Although patients are frequently
consulted, evidence that their involvement influences the research agenda remains limited. We propose a novel
model that allows patients and the public not only to propose research questions, but to design, initiate and
deliver their own research with all the necessary support from research professionals. We demonstrate the feasibility
and utility of this approach in reporting the establishment, experiences and progress of the Patient Led Research
Hub. Using this resource, patient organisations are now able to initiate and conduct rigorous clinical research
unfettered by the constraints of academic or economic agendas.
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The unmet need of patient led research
The design and delivery of clinical research and the set-
ting of research agendas have long been the domain of
academic researchers and industry. In industry, real or
perceived clinical needs are identified, but priorities are
almost invariably determined by economic consider-
ations. Industry sponsored trials necessarily select inter-
ventions, comparators and trial outcomes in order to
maximise the likelihood of success. Academic re-
searchers may not be equally driven by commercial con-
siderations, but instead are constrained by demands to
produce work that is highly cited, of high impact, and
most likely to result in further research funding. This
environment lends itself to relatively narrow research
programmes, often focused, topic specific and seldom
diverging from a defined research narrative.
Patient involvement in research is a relatively recent de-
velopment. The UK National Health Service launched the
NHS Research and Development Strategy in 1991 [1], pro-
posing patient involvement and engagement for the first
time. This was formalised with the establishment of the
‘Standing Advisory Group on Consumer Involvement in
the NHS Research and Development Programme’ in 1996,
aiming to improve the way research is prioritised, commis-
sioned, undertaken and disseminated [2]. Since then, there
has been a rapid proliferation of initiatives and opportun-
ities, with patient involvement now a prerequisite to re-
search funding by the National Institute for Health
Research (NIHR) and other grant organisations. Most fun-
ders ensure patient members serve on review panels and
contribute to peer review. However, the overwhelming ma-
jority of commissioned and open research calls remain an-
swered by academics or academic-industry partnerships. It
is the norm for applicants to seek patient involvement only
once research questions have been formulated and pro-
posals are in draft. Notwithstanding the very real impact
this approach has on the conduct of funded research, this
situation may reasonably be described as a form of token-
ism. The impact Patient and Public Involvement (PPI) ac-
tivities have had on research outcomes continues to be
questioned [3].
NIHR’s INVOLVE promotes PPI through a number of
initiatives, provides tailored information and resources
to patients and researchers, and hosts patient involve-
ment events and conferences. A recent publication
‘Guidance on co-producing a research project’ aims to
explain key principles and features important to realising
research with patients and public as equal stakeholders
[4]. The guidelines build on previous ‘Going the Extra
Mile’ recommendations to promote co-production as a
means of advancing traditional PPI, recognising the need
for flexible, patient-centred opportunities [5].
Also supported by the NIHR, the James Lind Alliance
(JLA) Priority Setting Partnerships have successfully
engaged patients and stakeholder groups in setting top ten
research priorities across a wide range of disease areas [6].
These partnerships and collaboration efforts are valuable,
but many priorities thus set never proceed to trial, and
those that do are commissioned with limited opportunity
for continued patient and stakeholder involvement [7].
Many charities, patient support organisations, and
disease-specific medical departments are also beginning to
support internal patient priority setting. The National
Cancer Research Institute and the Service User Research
Enterprise, for example, provide an encompassing ap-
proach to cancer [8] and mental health research [9], by
encouraging patients and service users to be involved
across all aspects of research. However despite these ef-
forts, a mismatch exists between patient priorities and in-
terventions researched in registered trials [10], consistent
with the observation that the research agenda of industry,
academics and patients only partially overlap [7].
In the United States, PCORI is focused on patient centred
outcomes, promoting patient involvement, and funding
patient centred research, but proposals submitted by
patients are internally prioritised and in turn commissioned
externally [11]. In Canada, SPOR similarly focusses on
patient-identified priorities and improved patient out-
comes, achieved through a multi-disciplinary approach
[12]. In Europe, organisations such as EUPATI focus on
patient education [13]. The overall landscape of PPI
initiatives are important and complementary, but do
not yet allow patients to propose, initiate and conduct
research in an independent manner. The net result is
that many questions that matter a great deal to patients
are never pursued or funded.
Establishing the Patient Led Research Hub
In 2015, the UK Polycystic Kidney Disease (PKD) Char-
ity approached members of the Cambridge Clinical Tri-
als Unit (CCTU) to consider a trial assessing high water
intake as a means of slowing polycystic kidney disease
progression. Despite this question being of high import-
ance to patients, the PKD Charity had been unable to
collaborate with an academic partner since its first pro-
posal in 2006. This experience highlighted the lack of re-
sources and opportunities for patient groups with
similarly unanswered questions, and led directly to the
establishment of the Patient Led Research Hub (PLRH).
PKD Charity and the PLRH have since successfully con-
ducted an externally funded, randomised controlled
feasibility trial (NCT02933268). Some of the feasibility
work and the design of the trial are described in two
joint publications [14, 15]. Following this success, a sec-
ond proposal from the PKD Charity focused on chronic
pain interventions in PKD; a high priority for patients
but unlikely to receive industry funding. The PLRH,
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PKD Charity and 8 patients, initiated work on this pro-
ject in 2017 with an international workshop to explore
the topic and consider feasible trial designs.
The PLRH aims to provide academic expertise in all as-
pects of research design and conduct, free from a defined
research agenda. This expertise is available to patients and
patient organisations to support patient-initiated and pa-
tient led research. Positioned within the CCTU, with close
ties to the University of Cambridge and Cambridge Bio-
medical Research Centre (BRC), core membership of the
PLRH consists of an experienced clinical trialist and a full
time research manager, with access to and input from
statisticians, health economist, grants officer, and other
expert members of the trials unit and School of Clinical
Medicine. This core operational membership does not
include patients or members of the public. Instead, over-
sight and input are sought from the Cambridge BRC PPI
Oversight Group (which includes several members of the
public), while patient members of the proposing group
become part of the study management team for each indi-
vidual PLRH project.
The PLRH was proposed to and supported by the
Cambridge BRC and CCTU at its inception; this support
includes funding for infrastructure and one full-time em-
ployee. Although independent of other local and regional
PPI initiatives, interaction with existing PPI initiatives is
maintained. The PLRH forms part of the Cambridge
University Health Partners PPI Working Group, East of
England Public Involvement in Research Partnership
Group, and UK Clinical Research Collaboration (UKCRC)
Patient Public Involvement and Engagement Task and
Finish Working Group, ensuring support from experienced
PPI Leads and access to public panels as needed. A process
(Fig. 1) for accessing and for partnering with the PLRH was
established in consultation with patient advisors, the
Cambridge BRC PPI Oversight Group, and the CCTU
Advisory Board. The PLRH and its activities are presented
online, via social media, newsletters, and through direct
contact with patient organisations.
The PLRH patient involvement model
Research ideas or specific proposals are welcomed from
any patient organisation or disease charity. Individual
patient proposers are encouraged to first establish a dia-
logue with a relevant patient organisation before con-
tacting the PLRH to foster a comprehensive support
network and enable group collaboration. To ensure all
proposals are considered equally without bias to patients
experienced in research, there is no standardised form
or set submission format. Proposals may be submitted
online, via email or through direct conversation, and
may be a simple idea or detailed project outline. Com-
munication with the patient group ensures the proposal
is thoroughly understood and translated into a viable
Fig. 1 PLRH workflow
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research question as intended. The PLRH is not a priority
setting organisation.
Tess Harris, patient and CEO of PKD Charity notes “I
was very impressed with the courtesy and professionalism
shown to me in 2015 when we approached the PLRH. I
was given time to explain why this was an important
unanswered research question; further meetings were
organised with relevant experts who gave time (pro bono)
from their busy schedules to explore further; we were
consulted and respected at every step; and listened as
co-applicants/authors as relevant.”
Once the research question is established, clinical trial-
ists and statisticians conduct a preliminary assessment.
The PLRH ethos is that, if a proposal is feasible and ad-
dresses an unmet need, it should be supported. The
feasibility assessment considers only technical and oper-
ational criteria: 1) What is already known? 2) What sam-
ple size is required? 3) Can sufficient numbers of
participants be recruited? 4) Is the proposed interven-
tion available? 5) Is the research ethical? 6) Are there
any potential funding sources? 7) What is the extent of
clinician involvement required, and would the relevant
clinicians support the research (for example, if medical
or surgical interventions form part of the research, it
may not be feasible without support from clinical staff )?
If feasibility is uncertain, further work is undertaken by
the PLRH and/or proposing group; this may include sys-
tematic reviews, patient surveys, or consultation with
third parties including patient organisations, charities,
funders, clinicians or academic researchers.
Decisions on feasibility are reached jointly with pro-
posers. To date, there have been no instances where the
feasibility decision has been disputed, but the PLRH
makes clear that adjudication of any disputed decisions
is possible through the Cambridge BRC PPI Oversight
Group. However, given that the feasibility assessment is
undertaken in partnership with proposers and that deci-
sions are reached jointly, the likelihood of disagreement
is small.
Infeasible proposals are not pursued, but the propos-
ing group is welcome to revise or submit a new idea at
any time. Feasible proposals that closely align with exist-
ing work are referred to the relevant research group or
programme. Feasible projects supported by the PLRH
require an ongoing partnership with the proposing
patient organisation; proposals may be deferred if the
proposing group is without capacity to lead the project.
A collaborative study team is formed, and proposers
maintain co-ownership of the emerging project, act as
co-applicants on funding applications and all subsequent
publications and retain intellectual property rights where
appropriate. The PLRH project manager facilitates
accessible and transparent dialogue throughout the
lifespan of each project, ensuring equal representation of
all stakeholders. Where large charities or patient organi-
sations are involved, a variety of involvement and en-
gagement opportunities are available to patient members
throughout the project. External experts and national re-
search groups are invited to contribute to project devel-
opment. PPI activities and project development work are
supported where possible through PLRH funds and ex-
ternal contributions (e.g. East of England Research De-
sign Service (RDS)). This multifaceted approach enables
competitive applications to public funders, research
charities or industry partners. If funding is achieved,
projects become autonomous to the extent possible to
allow PLRH resources to become available for new pro-
posals. Unsuccessful bids are reviewed in order to learn
from these submissions and improve subsequent submis-
sions. Retaining the ‘professional’ core PLRH membership
allows the transfer of learning to any resubmission or
similar future submissions in partnership with other
groups. Based on our progress and experience to date, the
PLRH intends to design a framework for future patient
involvement in patient led research.
PLRH progress: May 2015 – May 2018
The PLRH has received multiple high-quality research ideas
and proposals, ranging in topic from bench to bedside
(Fig. 2). Twenty-eight submissions were received between
May 2015 and May 2018, originating from 14 different pa-
tient organisations and 11 individual patients living with a
rare disease or mental health disorder. This number does
not reflect all correspondence, as some organisations com-
pile multiple proposals which are then prioritised based on
importance to patient members and feasibility.
Of submissions received, ten were not deemed technically
feasible, were already answered in the literature, or pro-
posers were unable to commit to the length of project. Two
general research ideas that focused on raising awareness
closely aligned with existing research programmes, and two
proposals that focused on new treatments for disease modi-
fication mirrored clinical trials early in development; in
each case the PLRH was able to facilitate collaboration
between proposers and the relevant research group. Of the
remaining 14 feasible proposals, two have become active
projects, two are awaiting funding announcements, and ten
are in varying stages of development (Fig. 3).
It has become clear from this activity that an unmet
need exists to support patients’ own research proposals.
Proposals received have had a striking focus on quality
of life, with 50 % of feasible proposals concentrated on
interventions to improve symptoms such as fatigue,
pain, itch or depression (Fig. 4).
Strengths and challenges of the PLRH model
The PLRH affords patients the ability to conduct
research independently, free from the constraints of
Mader et al. Research Involvement and Engagement  (2018) 4:21 Page 4 of 7
research strategy and interests that form an inextricable
part of most industry or academic research programmes.
This broad ethos enables patients to pursue research
questions that matter to them in a rigorous and un-
biased manner. To our knowledge, this is the first initia-
tive of its kind globally.
The PLRH approach has several strengths: it is the
only initiative to retain patient proposers as the drivers
of research from the very outset; and, given that pro-
posals originate with patient organisations, patients feel
a greater sense of partnership, leading to more rapid re-
cruitment, better participant adherence, and stronger
support of studies.
There are also challenges inherent to the PLRH model.
Projects often commence from a standing start, without
pre-existing literature reviews or meta-analyses. This re-
quires feasibility work which can be time and resource
intensive; such early work typically precedes funding ap-
plications, meaning that supporting resources need to be
raised separately. The nature of proposals is unpredict-
able, and although generic methodology is provided by
the PLRH and CCTU, highly specialised disease areas re-
quire support and leadership from experts in a given
field. While some investigators are very interested and
can provide capacity, others are unable to assist pro
bono, and still others view the PLRH with a considerable
degree of scepticism and decline to support its activities.
Secondly, core infrastructure and staffing are required to
maintain the PLRH. Since the initiative is both new and
unprecedented, the remit of existing funding streams
does not easily align with the focus of the PLRH. Finally,
it is clear that the PLRH approach is not suited to all as-
pects of clinical research. New drugs or devices will nat-
urally emerge from industry or academic research, and it
is not reasonable to expect that all highly technical stud-
ies should originate with patients.
Advancing the PLRH model
The PLRH is unique in remit and operation. The re-
cently published NIHR INVOLVE guidance of research
co-production cites the key co-production principles as
sharing of power, inclusion of perspectives, respecting
the value and knowledge of all contributors, reciprocity,
and the building of relationships [4]. The PLRH model
does more than align with these principles: it surrenders
power, is driven by patient perspectives with researchers
Fig. 2 Primary topic area of all received proposals
Fig. 3 PLRH project status (May 2018)
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rather than patients as reciprocators, and maintains the re-
lationship with patient partners as both the over-arching
and underpinning principle. Existing models and guidelines
for co-produced research focus on recognising patients and
the public as equal partners within the historical paradigm
of academic or industry-driven research. In contrast, we
propose a model that gives ‘power to the people’, with re-
searchers acting as servants and agents of a patient-dictated
research agenda.
Our early experience suggests that the PLRH model
addresses a need that is currently at best incompletely met
across the PPI landscape in the United Kingdom. As we
have not yet extensively advertised the PLRH, it is likely
that our report significantly underestimates the need for
this model of patient led research. There is an urgent
requirement to expand the capacity of the PLRH, and
indeed to replicate the PLRH model elsewhere. How this is
best achieved is the subject of ongoing discussions between
the PLRH, INVOLVE, UKCRC, East of England RDS,
regional research and involvement groups, and inter-
national groups such as PCORI, Canadian research centres,
and the International Clinical Trial Center Network. Na-
tional and international conference presentations on our
methods and early success have generated considerable
interest and support.
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